2R,4R)-1-(2-Hydroxymethyl-1,3-dioxolan-4yl)thymine (DOT) is a thymidine analogue that has potent in vitro activity against wild-type and nucleoside reverse transcriptase inhibitor (NRTI)resistant HIV. For nucleoside analogues to inhibit viral replication, they must be metabolized to the active triphosphate, which inhibits the viral reverse transcriptase (RT). Using purified enzymes, the kinetics of DOT phosphorylation, inhibition of wild-type and drug-resistant HIV-1 reverse transcriptase activity, and excision of DOT-5′monophosphate (DOT-MP) from a chainterminated primer were examined. DOT was phosphorylated by human thymidine kinase-1 (TK-1) but not by other pyrimidine nucleoside kinases, including the mitochondrial thymidine kinase (TK-2). Resistance to NRTIs involves decreased binding/incorporation and/or increased excision of the chain-terminating NRTI. RTs containing the D67N/K70R/T215Y/K219Q or T69S-SS/T215Y mutations show enhanced removal of DOT-MP from terminated primer as well as approximately fourfold decreased binding/incorporation. The Q151M and K65R mutations appear to cause decreased inhibition by DOT-TP. However, both the K65R and Q151M mutations show decreased excision, which would confer greater stability on the terminated primer. These opposing mechanisms could offset the overall resistance profile and susceptibility. Little or no resistance was observed with the enzymes harbouring mutations resistant to lamivudine (M184V) and non-nucleoside RT inhibitors (K103N).
Introduction
Nucleoside reverse transcriptase inhibitors (NRTIs) have a significant role in highly active antiretroviral therapy (HAART), as at least one NRTI is included in combination therapies (Van Vaerenbergh et al., 2002; Vandamme et al., 1998) . In order for NRTIs to inhibit viral DNA replication, they must be taken up by the infected cells, metabolized to the active triphosphate (TP), and incorporated into a newly synthesized DNA chain by HIV-1 reverse transcriptase (RT). All NRTIs currently approved by the Food and Drug Administration lack the 3′-hydroxyl group on the ribose ring or have a modified sugar moiety, and therefore act as chain-terminators. One of the major problems in current HIV chemotherapy is the development of drug-resistance mutations. Mutations associated with NRTI resistance cause increased discrimination of the drugs during DNA synthesis by RT or increased efficiency of removal of the chain-terminating nucleotide. One well known example of increased discrimination is the M184V mutation, which causes resistance to lamivudine (3TC) and other L-nucleosides (Schinazi et al., 1993; Schuurman et al., 1995) . The β-branched residue at position 184 sterically clashes with the incoming 3TC-TP. High-level resistance to zidovudine (AZT) was found to be associated with RT mutations M41L, D67N, K70R, L210W, T215Y/F and K219Q (Kellam et al., 1992; Larder & Kemp, 1989) . These mutations are termed thymidine-associated mutations (TAMs) because the mutations also decrease sensitivity to thymidine analogue stavudine (d4T; Lennerstrand et al., 2001; Shulman et al., 2002) . Pyrophosphorolysis is known to be the mechanism by which these mutations give rise to AZT resistance (Meyer et al., 1998; Meyer et al., 1999; Ray et al., 2003; Smith et al., 2005) . This mechanism of resistance involves the removal of AZT-monophosphate (MP) from the primer terminus, thus allowing strand synthesis to continue. The physiological pyrophosphate donor is believed to be ATP (Meyer et al., 1998; Smith et al., 2005) , but pyrophosphate might have a role in the mechanism of resistance (Ray et al., 2003) .
(-)-(2R,4R)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)thymine (DOT; Figure 1 ) is a thymidine analogue being developed as an anti-HIV agent that has demonstrated potent activity in vitro against wild-type HIV and a broad range of NRTI-resistant viruses including those with mutations K65R, L74V, M184V, T215Y, M184V/T215Y and D67N/K70R/T215Y/K219Q (Chong & Chu, 2004; Chu et al., 2005; Kim et al., 1992) . Chu et al. showed that viruses containing all these mutations were as sensitive to inhibition by DOT as was wild-type virus . Computer modelling studies suggested that DOT-TP binds to a wide-variety of mutant RTs . A preliminary study of the inhibition of wild-type and mutant HIV-1 RT activity by DOT-TP was presented at the 13th Conference on Retroviruses and Opportunistic Infections by Lennerstrand et al. (http://www.retroconference.org/2006/ Abstracts/26992.htm) and at the XIV International HIV Drug Resistance Workshop by Schinazi et al. (2005) . In our report, the molecular mechanism action of DOT was further explored in order to understand the mechanism of DOT activity against various NRTI-resistant viruses. We examined the phosphorylation of DOT by human nucleoside kinases and investigated the inhibition of wild-type and NRTI-resistant HIV-1 RTs, as well as the ATP-mediated removal of DOT-MP by wild-type and AZT-resistant (AZT-R) mutant HIV-1 RTs.
Materials and methods

Materials
DOT was synthesized stereoselectively from an optically pure intermediate, 2-(R)-benzoyloxymethyl-1,3-dioxolane-4-(R)-carboxylic acid, based on the procedures described previously ( Janes et al., 1999) . The enantiomeric purity of DOT (>99.9%) was determined by HPLC using a Chiralpak column (Chiral Technologies Europe, Illkirch Cedex, France). DOT-TP was synthesized as described previously (Burgess & Cook, 2000) and purified by HPLC using a 250 mm×41 mm Microsorb C18 Column (Varian, Inc., Palo Alto, CA, USA). The purity of DOT-TP was >92% by HPLC using a PARTISIL 10 SAX WCS Analytical Column, 4.6 mm×250 mm (Whatman, Florham Park, NJ, USA) and the molecular mass was confirmed by a MICROMASS Quattro micro API LC/MS/MS unit (Waters, Milford, MA, USA). AZT-TP was purchased from Trilink Biotechnologies (San Diego, CA, USA). [α-32 P]dTTP and [γ-32 P]ATP were purchased from GE Healthcare (Piscataway, NJ, USA). Oligonucleotides D23A, D23B and D45 (Table 1) were synthesized and polyacrylamide gel purified by OPERON (Huntsville, AL, USA). The R36 oligonucleotide was synthesized and purified by New England Biolabs (Ipswich, MA, USA). Annealing of primer/template was performed by adding the oligonucleotides at a molar ratio of 1:1.4 and heating the mixture at 90°C for 5 min followed by slow cooling to 50°C over 15 min. The mixture was placed on ice for another 10 min. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA)
5′-GCC TCG CAG CCG TCC AAC CAA CT-3′ 3′-CGG AGC GTC GGC AGG TTG GTT GAG TTG GAG CTA GGT TAC GGC AGG-5′ D23B/R36 5'-TC AGG TCC CTG TTC GGG CGC CAC-3′ 3′-CGA AAG UCC AGG GAC AAG CCC GCG GUG ACG AUC UCU-5′ D23B/D36 5'-TC AGG TCC CTG TTC GGG CGC CAC-3′ 3′-CGA AAG TCC AGG GAC AAG CCC GCG GTG ACG ATC TCT-5′ D23DOT-MP/D36 5'-TC AGG TCC CTG TTC GGG CGC CAC X-3′ 3′-CGA AAG TCC AGG GAC AAG CCC GCG GTG ACG ATC TCT-5′ X, (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)thymine monophosphate. 
Enzymes
Thymidine kinase 1 and 2 (TK-1 and TK-2) were cloned from total RNA from human HepG2 cells into Escherichia coli expression vectors pTrcHisA (Invitrogen, Carlsbad, CA, USA) and pQE60 (Qiagen, Valencia, CA, USA), respectively. The resulting constructs were co-transformed into XL1-Blue MRF′-competent E. coli cells (Stratagene, La Jolla, CA, USA) along with plasmid pRep4 (Qiagen, Valencia, CA, USA), which codes for the lac repressor protein. The enzymes were purified by metal-affinity chromatography using Talon resin (Clontech, Mountain View, CA, USA). Uridine-cytidine kinase 1 (UCK-1), 2′-deoxycytidine kinase (dCK) and HIV-1 RT were expressed and purified as described previously (Kati et al., 1992; Murakami et al., 2007) . HIV-1 RT enzymes containing drug-resistance mutations were created using a Quikchange mutagenesis kit (Stratagene, La Jolla, CA, USA) except for the T69S-SS/T215Y mutant clone which was kindly provided by Dr Stephen Hughes at National Cancer Institute, Frederick, MD, USA.
Phosphorylation assays
Phosphorylation of DOT by human TK-1, TK-2, dCK and UCK-1 was studied spectrophotometrically as described previously (Murakami et al., 2007) . The reaction was coupled with pyruvate kinase (PK) and lactate dehydrogenase (LDH), and oxidation of NADH was followed at 340 nm using a Lambda 35 UV/Vis Spectrometer (Perkin Elmer, Boston, MA, USA). All assays were performed at 25°C in a 1 ml reaction containing 64 mM Tris-HCl pH 7.5, 3.8 mM EDTA, 180 mM KCl, 12.8 mM MgCl 2 , 24 mM (NH 4 ) 2 SO 4 , 1 mM ATP, 0.5 mM phosphoenolpyruvate, 0.1 mM NADH, 5 IU/ml PK, 13.8 IU/ml LDH, nucleoside substrate and kinase. The reaction rate at different concentrations of the nucleoside substrate was determined for each enzyme and steady-state parameters were calculated using GraFit program version 5 (Erithacus Software, Horley, Surrey, UK).
HIV-1 RT assays
HIV-1 RT reaction was studied by monitoring incorporation of 32 P-labelled dTMP into the elongating DNA strand. A steady-state reaction was performed in a total volume of 40 μl containing 1 μM primer/template, 50 nM HIV-1 RT, 100 μM each of dATP, dGTP and dCTP, the appropriate amount of [α-32 P]dTTP and varying concentrations of dTTP and DOT-TP in 50 mM Tris/HCl buffer pH 7.5 and 5 mM MgCl 2 . The reaction was performed at 37°C. After 5, 10 and 15 min, 10 μl aliquots were taken and the reaction was quenched by mixing with 10 μl of 50 mM EDTA stop solution.
The radiolabelled products were quantified using the Whatman DE81 paper assay (Bryant et al., 1983) . A 5 μl sample of the quenched reaction mixture was spotted on a sheet of DE81 paper. After drying, the paper was washed three times for 5 min with 0.3 M ammonium formate, pH 8.0. After rinsing the paper once with water and once with ethanol, the paper was dried and exposed to a phosphor screen and radioactive spots were visualized by a phosphorimager. The spots were also cut out of the paper and the radioactivity was counted in a liquid scintillation counter. The amount of radiolabelled dTMP incorporated into the primer was calculated on the basis of the total radioactivity in 1 μl of the quenched reaction.
The rate of the reaction was determined from the slope of the time course of product formation. To determine the inhibition constant, K i , reaction rates from reactions containing different concentrations of substrate and inhibitor were determined and fit to a competitive inhibi-
is the maximum rate, K m is the Michaelis constant and K i is the inhibition constant. A non-linear fit was performed using GraFit program version 5 (Erithacus Software, Horley, Surrey, UK).
Removal of DOT-MP.
An oligonucleotide chain-terminated with DOT-MP (D23-DOTMP) was synthesized using HIV-1 RT as described previously ( Johnson et al., 2001) . It was radiolabelled at the 5′-end using [γ-32 P]ATP and polynucleotide kinase (New England Biolabs, Ipswich, MA, USA) as described previously (Kati et al., 1992) . Removal of nucleoside analogue monophosphate from the chain-terminated primer was studied as described previously (Basavapathruni et al., 2004; Ray et al., 2003) . The reaction mixture contained 50 nM D23-DOTMP/D36, 250 nM wild-type or NRTI-resistant HIV-1 RT, 10 mM MgCl 2 , and a varied amount of ATP in 50 mM Tris/HCl pH 7.6 buffer. The ATP used in this study was pre-treated with inorganic pyrophosphatase (Roche Applied Science, Indianapolis, IN, USA) to remove contaminating pyrophosphate. At the desired times the reaction was quenched in 0.3 M EDTA (final concentration) and the product was separated on a 20% polyacrylamide DNA sequencing gel, analysed by a BioRad Molecular Imager FX System and quantified by BioRad Quantity One software (BioRad, Hercules, CA, USA). The data were fit to a single exponential decay equation: (Intact substrate)= Aexp(-k rem t)+C, where A is the amplitude, k rem is the rate of removal, t is the time in seconds and C is the amount of unreacted substrate.
Results
Phosphorylation of DOT
In order for NRTIs to inhibit the target enzyme, HIV-1 RT, they must be phosphorylated to their active triphosphate forms by host cellular kinases and Schinazi et al. have reported that DOT appears to be phosphorylated to DOT-TP through a TK-dependent mechanism . Here, we tested the ability of TK-1, TK-2, dCK and UCK-1 to catalyse the phosphorylation of DOT to DOT-MP. As shown in Table 2 , only TK-1 was able to phosphorylate DOT. DOT was phosphorylated by TK-1 approximately 250-fold less efficiently than was the enzyme's natural substrate, thymidine. The dependence of phosphorylation rate on DOT concentration is shown in Figure 2 .
Inhibition of HIV-1 reverse transcriptase
The inhibition of wild-type and NRTI-resistant HIV-1 RT by DOT-TP was examined under steady-state kinetic conditions using either a primer/template with a random sequence (D23A/D45) or a primer/template with an HIV genomic sequence (D23B/R36 and D23B/D36). The sequences of these oligonucleotide substrates are shown in Table 1 . The reactions were performed in the presence of varying concentrations of dTTP and saturating concentrations of the other three dNTPs (100 μM each). Although dNTP can act as a pyrophosphate donor for the excision reaction, there should be little or no effect in our incorporation assays. Figure 3 shows an example of inhibition of the wild-type RT by DOT-TP during DNA-directed DNA synthesis using D23A/D45 as a primer/template. All data points were globally fit to a competitive inhibition equation and the Michaelis constant (K m ) and inhibition constant (K i ) were determined. The K i /K m ratio was calculated for each enzyme to compare the degree of inhibition of wild-type RT with that of the different mutant enzymes.
Kinetic parameters for the mutant enzymes using the D23A/D45 primer/template are summarized in Table 3 . None of the mutations significantly affected the K m for Results given as mean ±SD. dCK, 2′-deoxycytidine kinase; DOT, (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)thymine; TK-1, human thymidine kinase-1;TK-2, mitochondrial thymidine kinase; UCK-1, uridine-cytidine kinase 1. dTTP. A parameter of fold difference in K i /K m was calculated by (K i /K m for mutant)/(K i /K m for wild-type). This parameter represents fold resistance at the enzyme level. The greatest increase in K i /K m was observed with the Q151M mutant (19-fold) whereas only a moderate increase was seen with K65R (8.3-fold), AZT-R (4.3-fold) and T69S-SS/T215Y (4.3-fold) mutants. Little or no change was observed with RT containing either the M184V mutation or the K103N mutation.
The inhibition of RT activity by DOT-TP was also studied using the D23B/D36 and D23B/R36 primer/templates, which contained HIV-1 genomic sequences, to examine whether the inhibition profile of DOT-TP is sequence specific. The K m and K i values were determined and K i /K m was calculated as described above. The kinetic parameters determined using these primer/templates are shown in Table 4 . As observed with the random D23A/D45 primer/template, there was no significant difference in the K m values for dTTP for wildtype or mutant RTs with either the DNA or RNA template. Moderately increased K i /K m values were observed with DNA and RNA templates for K65R (4.8-to 8.1-fold), Q151M (6.5-to 6.9-fold) and T69S-SS/T215Y (4.1-to 4.4-fold) mutants. In order to validate our results, the inhibition of wild-type and K65R enzymes by AZT-TP was compared using the D23B/D36 primer/template. A 50% inhibitory concentration analysis demonstrated that K65R was 2.6-fold resistant to AZT-TP (data not shown), which was consistent with previously published data where K65R showed up to 4-fold resistance to AZT-TP (White et al., 2005) . The same experiment with DOT-TP showed 7.6fold resistance which was very similar to our K i /K m data with the D23B/D36 primer/template (8.1-fold). The M184V and AZT-R mutants showed slightly increased K i /K m values of approximately two to threefold. No significant effect was observed with the K103N mutant RT.
ATP-mediated removal of DOT-MP
Because AZT resistance is believed to be the result of increased efficiency of AZT-MP removal, removal of DOT-MP from the chain-terminated primer was studied. Reactions were performed under single-turnover conditions where the enzyme was in excess of the DNA substrate. The amount of rescued DNA substrate was quantified at desired times and the removal rate and the amount of DOT-MPterminated primer was determined ( Figure 4A & 4B) . Recent reports showed that an ATP-mediated removal product, dinucleoside tetraphosphate, can serve as a substrate for reincorporation (Dharmasena et al., 2007; Meyer et al., 2006) . As described in Materials and methods, our removal assay contains 50 nM terminated primer, so the concentration of the dinucleoside tetraphosphate cannot be higher than 50 nM. In the study by Meyer et al., little reincorporation was demonstrated at a dinucleoside tetraphosphate concentration of 50 nM (Meyer et al., 2006) . Therefore, under our experimental conditions, reincorporation of the dinucleoside tetraphosphate product should have little or no effect on activity. Removal of DOT-MP showed complex kinetics as the DOT-MP removal rate was independent of ATP concentration and the percentage amplitude followed hyperbolic dependence ( Figure 4C & 4D) . At 6 mM ATP, the DOT-MP removal rate was slow with both wild-type and AZT-R mutant enzymes, possibly because of substrate inhibition. The dissociation constant (K d ) for ATP was calculated by fitting the percentage amplitude at each ATP concentration to a hyperbolic equation. The data are summarized in Table 5 . For comparison, previous AZT-MP removal data are included (Basavapathruni et al., 2006) . The AZT-R RT was able to remove DOT-MP 4.6-fold more efficiently than the wild type, and it was consistent with AZT-MP removal (6.9-fold). Subsequently, the rate of ATP-mediated removal of DOT-MP by various drug-resistant RTs was determined at a physiologically relevant concentration of ATP (3 mM). As shown in Table 6 , the removal rate was approximately seven times faster with the AZT-R and the T69S-SS/T215Y mutants than with the wild type. Interestingly, K65R and Q151M showed an opposite effect with a 3-to 4-fold lower rate than wild type. The rates with M184V and K103N were very similar to the rate obtained with wild type.
Discussion
It has been suggested that DOT is a thymidine-kinasedependent nucleoside analogue Schinazi et al., 2005) ; however, a careful enzymatic characterization of this activity with human enzymes has not been published. Here we provide enzymatic evidence that DOT is indeed phosphorylated by thymidine kinase. Phosphorylation of DOT to DOT-MP was examined with various pyrimidine kinases including TK-1, TK-2, dCK and UCK-1. Only cytosolic thymidine kinase (TK-1) phosphorylated DOT, suggesting that the activation of DOT is strictly dependent on TK-1. Interestingly, DOT was not a substrate for the mitochondrial enzyme (TK-2), indicating that even if DOT is taken up by mitochondria it is not phosphorylated to the 5′-monophosphate. This observation is consistent with the previous report that DOT was not toxic in mitochondria .
In order to ascertain whether there is a sequence specificity in inhibition of HIV-1 RT by DOT-TP, the effect of DOT-TP on the activity of wild-type and various mutant RTs was examined using the random sequence primer/template D23A/D45 and primer/templates D23B/D36 and D23B/R36, which contain an HIV genomic sequence. The K m values for dTTP for each of the enzymes were not significantly affected by sequence differences in these primer/templates (Tables 3 & 4) . No differences were seen in the K i values determined for DOT-TP using either the D23B/D36 or the D23B/R36 primer/template. However, the K i values for DOT-TP were different with the D23A/D45 random sequence primer/template than with the genomic sequence primer/templates. In all the cases, the K i values determined with the random D23A/D45 sequence were lower than with the genomic sequences. It is possible that HIV-1 RT recognizes the genomic sequence and weakens binding of the inhibitor. Nevertheless the overall pattern of resistance to DOT-TP, as measured by comparing the fold differences in K i /K m for wild-type RT versus drug-resistant RTs, was consistent (all within 3-fold) between the different primer/templates. Our results indicate that the profile of DOT-TP resistance at the enzyme level was not affected significantly by the sequence of the primer/template. It was also important to examine the excision of DOT-MP from the chain-terminated primer because it is known that in some cases resistance to AZT is associated with an increase in the removal rate (Meyer et al., 1998; Smith et al., 2005) . As shown in Table 6 , the rate of ATPmediated removal of DOT-MP with different drug-resistant mutant RTs was determined in the presence of a physiologically relevant concentration of ATP (3 mM). Recently, it has been reported that the dinucleotide tetraphosphate from ATP-mediated pyrophosphorolysis of AZT-MPterminated primers can be reincorporated into the rescued primer and can inhibit DNA synthesis (Dharmasena et al., 2007; Meyer et al., 2006) . It also inhibited removal of AZT-MP at low concentrations of the dinucleoside tetraphosphate (Dharmasena et al., 2007) . Experiments are ongoing to examine whether a similar process might occur with DOT-MP removal.
We have examined both incorporation and removal of DOT-MP with wild-type and six drug-resistant mutant RTs. In order to understand the resistance profiles of In case of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)thymine monophosphate (DOT-MP) removal, the amount of chain-terminated DNA substrate reacted increased as the ATP concentration was increased and the removal rate was independent of the ATP concentration. Thus, the k rem values shown on the table are the maximum rates observed in the experiments. *Results given as mean ±SD. † Previous data obtained under the same experimental conditions (Basavapathruni et al., 2006) . AZT-MP, zidovudine monophosphate; AZT-R, zidovudine-resistant. Results given as mean ±SD. DOT-MP, (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)thymine monophosphate; RT, reverse transcriptase. Table 6 . ATP-mediated removal of DOT-MP by wildtype and mutant RTs in the presence of 3 mM ATP these mutants, effects of each mutant enzyme are discussed below. The K65R and Q151M mutants showed similar profiles in both incorporation and removal reactions. These mutant enzymes showed an increase in K i /K m for DOT-MP incorporation and decrease in DOT-MP excision rate. The K65R mutant showed 4.8-to 8.3-fold increase in K i /K m for DOT-TP. A recent report proposed that the mechanism of K65R resistance to NRTIs is a combination of effects involving incorporation and excision (White et al., 2005) . In the study, the K65R mutant RT discriminated tenofovir-DP, ddATP, 3′-azido-2′,3′dideoxyadenosine-TP, carbovir-TP (active form of abacavir), AZT-TP, d4T-TP, 3TC-TP and emtricitabine-TP. However, at the same time the K65R enzyme decreased the rates of AZT-MP, d4T-MP, carbovir-MP and tenofovir removal. These two opposing effects could explain why moderate-to high-level enzymatic resistance to d4T-TP (5-to 48-fold) was seen with the K65R mutant enzyme but little or no resistance was found in cell culture (Garcia-Lerma et al., 2003) . It has been reported that no resistance to DOT was observed with the virus containing the K65R mutation in cell culture . It is possible that DOT presents properties similar to d4T-TP because we saw only moderate resistance to inhibition by DOT-TP with the K65R enzyme and 2.5-fold decrease in excision rate at the enzyme level.
Of the mutant enzymes tested, Q151M showed the highest increase in K i /K m , especially when the random D23A/D45 substrate was used (19-fold). This mutation is known to confer multidrug resistance and is found in patients treated with d4T (Kosalaraksa et al., 1999; Maeda et al., 1998) . On the basis of computer modelling and kinetic studies, the molecular mechanism of resistance to ddNTP by the Q151M mutation has been proposed to be unstable positioning of incoming ddNTP (Deval et al., 2002) . When the removal of DOT-MP was studied with Q151M enzyme, the rate decreased fourfold compared with the wild type. Similarly to what was seen with K65R, the two opposing effects (decreased incorporation and decreased removal rate) might compensate for each other, and the overall effect of the Q151M mutation on DOT activity might not be significant.
In the case of the AZT-R mutant enzyme, inhibition by DOT-TP was slightly reduced (1.5-to 4.3-fold). Although the mechanism of AZT resistance is believed to be ATP-mediated removal of chain-terminated AZT-MP, previous pre-steady-state kinetic studies have shown that there are subtle effects on incorporation of AZT-MP during both the initiation and elongation steps of DNA synthesis (Kerr & Anderson, 1997; Vaccaro & Anderson, 1998) . In addition, Lacey et al., have reported that under steady-state conditions, the AZT-R enzyme showed 2-to 4-fold higher K i for d4T-TP and 3′-amino-TTP than the wild type (Lacey et al., 1992) . In our removal study, the efficiency of DOT-MP removal was 4.6-fold higher with the AZT-R RT than the wild-type (Table 5) . This result was similar to that obtained for AZT-MP removal where a 6.8-fold increase in removal efficiency was seen. Although this result suggests the possibility of cross-resistance to DOT, it was shown that AZT-resistant virus containing the D67N, K70R, T215Y and K219Q mutations was sensitive to DOT in cell culture . Previous experiments with d4T-MP removal (Ray et al., 2003) showed similar results with a 4.4-fold increased removal efficiency for the mutant and no cross-resistance to d4T in cell culture (Larder et al., 1990) . However, patients with the mutations associated with AZT resistance showed decreased sensitivity to d4T (Shulman et al., 2001) .
The T69S-SS/T215Y mutant showed a similar inhibition profile to the AZT-R mutant enzyme with approximately a fourfold decrease in inhibition of DNA polymerization and sevenfold increase in removal rate at 3 mM ATP. When the T69S-SS mutation is coupled to a TAM, RT becomes resistant to all currently approved NRTIs (White et al., 2004) .
The inhibition of the enzyme by DOT-TP was not affected by the M184V and K103N mutations. This observation was not surprising as M184V is typically resistant to unnatural L-isomers including 3TC (Feng et al., 2004; Ray et al., 2002; Sarafianos et al., 1999) and K103N is resistant to non-nucleoside inhibitors whose binding site is ~10 Å away from the polymerase active site (Bacheler et al., 2000; Richman et al., 1994) . Furthermore, the removal rates for M184V and K103N RT were also very similar to that for wild type. Our enzyme data for M184V was also consistent with previous cell culture results . Therefore, overall, these mutations have no effect on interactions between DOT-TP and RT.
In summary, binding and incorporation of DOT-TP was not affected by different primer/templates. RTs containing Q151M and K65R mutations showed increases in K i /K m of 6.5-to 19-fold and 4.8-to 8.4-fold, respectively, compared with the wild type. Other mutant enzymes did not show significant increases in K i /K m . When the ATP-mediated DOT-MP removal activity was examined, RTs containing AZT-R and T69S-SS/T215Y mutations increased the rate of DOT-MP removal approximately sevenfold. Enzyme containing either the K65R or the Q151M mutation showed decreased inhibition of DNA polymerization as well as a decrease in the rate of excision which would confer greater stability to the terminated primer. These two opposing mechanisms could offset the overall resistance profile and susceptibility.
